对比厄洛替尼和吉非替尼靶向治疗非小细胞肺癌脑转移的临床效果

目的 探讨非小细胞肺癌脑转移患者采用厄洛替尼和吉非替尼靶向治疗的临床效果及安全性.方法 64例非小细胞肺癌脑转移患者中34例患者采用吉非替尼口服治疗,30例患者采用厄洛替尼治疗.对比2组患者近、远期疗效,生活质量以及不良反应的发生情况.结果 2组患者治疗2个月后,吉非替尼组疾病控制率稍高于厄洛替尼组,有效率稍低于厄洛替尼组,但差异无统计学意义(P＞0.05);2组患者2年生存率无明显差异(P＞0.05).厄洛替尼组各项不良反应发生率较吉非替尼组明显增高,差异具有统计学意义(P＜0.05).2组患者治疗2个月后,吉非替尼组Karofsky生活质量评分有效率明显高于厄洛替尼组,差异具有统计学意义(P＜0.05).结论 吉非替尼和厄洛替尼对NSCLC脑转移患者均有较好的治疗效果,但吉非替尼不良反应发生率较低,生活质量较高.

Clinical Effect of Erlotinib Versus Gefitinib Targeted Therapy for Non-small Cell Lung Cancer Patients with Brain Metastases

Objective To investigate clinical effect and safety of erlotinib versus gefitinib targeted therapy for non-small cell lung cancer patients with brain metastases.Methods A retrospective analysis was performed in 64 non-small cell lung cancer patients with brain metastases.Among the involved patients,34 patients were treated with oral gefitinib and 30 patients were given erlotinib.Short-term and long-term efficacy,life quality and adverse reactions in the 2 groups were compared.Results After 2 months of treatment,the disease control rate in the gefitinib group was slightly higher and the effective rate was slightly lower than that in the erlotinib group,the difference was not statistically significant (P ＞ 0.05).There was no significant difference in the 2-year survival rates between the 2 groups(P ＞ 0.05).The incidence of adverse reaction in the erlotinib group was significantly increased compared with the gefitinib group (P ＜ 0.05).After 2 months of treatment,Karofsky life quality score in gefitinib group was significantly higher than erlotinib group,the difference was statistically significant (P ＜ 0.05).Conclusion Both gefitinib and erlotinib are effective for non-small cell lung cancer patients with brain metastases,but gefitinib has lower incidence of adverse reactions and better quality of life.